Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Core Insights - Esperion's partner HLS Therapeutics has received approval from Health Canada to market NILEMDO for LDL-Cholesterol reduction in Canadians at risk of cardiovascular disease, with a commercial launch expected in Q2 2026 [1][2]. Company Overview - Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with elevated LDL-C and cardiovascular disease risk, including the only FDA-approved oral, once-daily, non-statin medications [4]. - The company is advancing its next-generation program aimed at developing ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [4]. Market Context - Approximately 2.6 million Canadian adults are diagnosed with heart disease, making it the second leading cause of death in Canada, with 14 adults dying every hour due to this condition [3].